Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Avita Medical Completes ISO Quality Audit, CE Mark Recertification


Avita Medical Completes ISO Quality Audit, CE Mark Recertification

NORTHRIDGE, CA and CAMBRIDGE, UNITED KINGDOM -- (Marketwire) -- 02/13/13 -- Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY)


 
--  SUCCESSFUL COMPLETION OF ISO QUALITY RECERTIFICATION AUDIT
--  RECEIVES ISO 9000, ISO 13485 AND MED DEVICE DIRECTIVE RECERTIFICATION
--  FREE TO CE MARK ALL REGENERATIVE AND RESPIRATORY PRODUCTS FOR SALE IN
    THE EUROPEAN UNION

Regenerative medicine company Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY) today announced that it has received formal notification of successful completion of the annual ISO Quality Recertification Audit conducted 8-9 January 2013. The Quality Audit, conducted by an independent, external auditor of the European Notified Body, covered all applicable elements of ISO 9001:2008 Quality Management System Certification, ISO 13485:2003 Medical Devices Certification, Medical Devices Directive 93/42/EEC and Canadian Medical Devices Regulation Part for Avita's Class III Medical Devices. No Major or Minor Non-Conformances were identified in the audit.

The ISO Quality Audit is a rigorous and comprehensive recertification audit to all of the required elements of the directives; successful ISO recertification is a requirement in order for Avita Medical to maintain its CE mark on its regenerative and respiratory products for sale within the European Union and Canada as well as a reference for registration in other countries, including the Middle East and Russia.

The audit addressed all phases of Avita Medical's Quality, Manufacturing and Management Systems as well as a comprehensive review and verification of controls on its portfolio of medical products including the Regenerative product, ReCell(R) Spray-On Skin(R), and the company's respiratory products (Funhaler(R) and Breath-A-Tech(R)).

Mr. William Marshall, Avita Medical's VP Operations and Regulatory, said: "Avita maintains a strong commitment to the quality of our products and to our customers. We continue to improve and streamline the company's Quality System and we are very pleased with the result of the audit."

"Tight control of Quality and Manufacturing Systems are a prerequisite for efficient operations," said Mr. Timothy Rooney, Chief Financial Officer and Chief Operating Officer. "The company has in place a formal Continuous Improvement system which has yielded significantly improved margins and reductions in operating costs. This is part of an on-going effort to deliver the highest quality products to our customers while maximizing efficiency of manufacturing and operations."

ABOUT AVITA MEDICAL LTD.

Avita Medical (http://www.avitamedical.com/) develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary tissue-culture, collection and application technology provides innovative treatment solutions derived from a patient's own skin. The company's lead product, ReCell(R) Spray-On Skin(TM), is used in a wide variety of burns, chronic wounds, plastic, reconstructive and cosmetic procedures. ReCell is patented, CE-marked for Europe, TGA-registered in Australia, and SFDA-cleared in China. ReCell is not available for sale in the United States; in the US ReCell is an investigational device limited by federal law to investigational use. An FDA trial on the safety and efficacy of ReCell is in process.

Contact: Avita Medical Ltd. Stella Sung, Ph.D. Business Development Officer Phone:+1 838-352-9400 Email: ssung@avitamedical.com

Investor Relations: ProActive Capital Resources Group, LLC Jeff Ramson CEO 641 Lexington Avenue, 6th Floor New York, NY. 10022 Phone:+1 646-863-6893 Email: jramson@proactivecapitalgroup.com

Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement